Background: Used as single agents, paclitaxel and topotecan have demonstrated promising activity in treating patients with relapsed aggressive non-Hodgkin's lymphoma (NHL). We conducted a phase II clinical trial to investigate the activity and tolerability ol" the cdmBirfStfon of both drugs.
Introduction
During the last three decades the incidence of nonHodgkin's lymphoma has increased, while the cure rate has not significantly improved [1, 2] . Patients with aggressive NHL who fail to respond to their induction therapy or who relapse from complete remission (CR) are frequently treated with salvage therapy. Because the duration of second remissions is usually short, patients who respond to salvage therapy are frequently given high-dose chemotherapy followed if possible, by stem cell transplantation. The most frequently used salvage regimens are arabinosyl cytosine (Ara-C)/platinum-or ifosfamide-based [3] [4] [5] [6] . Patients who fail to respond to these first-line salvage regimens or who relapse after responding have limited options for palliation or for effective tumor reduction in preparation for stem cell transplantation.
Used alone, paclitaxel and topotecan have each been reported to induce clinical remissions in 50% and 43% of patients with relapsed non-refractory aggressive NHL, respectively [7, 8] . Based on this promising single-agent activity, we combined paclitaxel and topotecan in a phase II study in patients with refractory or relapsed aggressive NHL. We found this combination to be effective in approximately half of the patients. Therefore, paclitaxel plus topotecan is an effective first or second line cytoreductive program for patients with relapsed or refractory aggressive NHL prior to bone marrow or stem cell transplantation. This chemotherapy could also serve as the basis for new combination program that could be tested in previously untreated patients with risk factors for poor outcome who are unlikely to respond to cyclophosphamide / hydroxydaunomycin /Oncovin / prednisone (CHOP) or CHOP-like programs [9] .
investigator's discretion. Response evaluation and duration of response were determined according to the guidelines of a recently published international workshop [12] .
Patients and methods Results

Patient selection
Patients were eligible for this trial if they were at least 18 years of age, and had bidimensionally measurable recurrent or refractory aggressive NHL of the following histologies according to the Revised EuropeanAmerican Lymphoma classification [10] : diffuse large B-cell lymphoma, folhcular center cell grade 111 (folhcular large), Ki-I anaplastic large-cell lymphoma, or peripheral T-cell lymphoma. Patients with transformed B-cell lymphoma were also eligible. Patients must have had no more than two prior treatment regimens, with the most recent anti lymphoma therapy given at least four weeks prior to starting paclitaxel plus topotecan treatment. Patients were required to have a performance status of < 2 on the Zubrod scale, an absolute neutrophil count = 1,500/ul, a platelet count = 100,000/ul, a bilirubin level < 1.5 mg/dl, serum glutamic-oxalopretic transaminase and serum glutomate pyruvate transaminase levels lower than twice the upper-normal values, and a serum creatinine level < 1.8 mg/dl. All patients were required to sign an Institutional Review Board-approved consent form. Patients were excluded if they had human immunodeficiency virus (HIV) infection; lymphoma involved in the central nervous system; a history of serious cardiac disease, such as myocardial infarction, within six months of study treatment; bradycardia or tachycardia; prior therapy with paclitaxel or topotecan; prior treatment with high-dose chemotherapy and stem cell or bone marrow transplantation; or active infection. The study also excluded women of childbearing age who were pregnant or not practicing adequate contraception.
Procedures for measuring and determining the extent of disease were required to be performed within three weeks prior to registration and included a complete blood count (CBC) with differential, platelet counts, a chemistry profile, and HIV testing. All patients had a chest X-ray; computed tomographic scans of the chest, abdomen, and pelvis; a gallium scan; and bilateral bone marrow biopsies and aspirates.
Study design
All patients were prcmedicated with dexamethasone 20 mg orally given four hours before paclitaxel infusion. Thirty minutes before paclitaxel infusion, patients were premedicated with intravenous infusions of dexamethasone 20 mg. diphenhydramine 50 mg, and cimetidine 300 mg. Treatment consisted of paclitaxel 200 mg/nr infused intravenously over three hours on day one and topotecan 1 mg/m 2 given intravenously over 30 minutes daily on days one through five. The dosages and schedule used in this study were adopted from a phase I trial previously reported by Lilenbaum and colleagues [11] . Twentyfour hours after the completion of chemotherapy, patients received daily subcutaneous injections of filgrastim (granulocyte colony-stimulating factor) 5 ug/kg unl >l tne neutrophil count reached 3000/ul. Treatments were repeated every three weeks in an outpatient setting. Patients who had disease progression after any course were removed from the study. Patients who achieved a PR or CR after a minimum of two courses were continued on study medication for a maximum of six courses or, if eligible, were offered high-dose chemotherapy and stem cell transplantation.
Patients had a CBC with differential and platelet counts twice weekly while on therapy and had a chemistry profile before every course. All imaging studies were repeated every two to three courses and after completion of therapy. Follow-up observations after completion of treatment consisted of a physical examination, CBC, chemistry profile, and imaging studies every three months during the first year, every four months during the second year, and every six months during the third year. Bone marrow biopsies were repeated if indicated at the
Patient characteristics
Seventy-one patients were eligible for this clinical trial. One patient withdrew for personal reasons before starting therapy. One patient was lost to follow-up after receiving one course of therapy, and three patients were prematurely removed from the study by their attending oncologist, in violation of study guidelines, after receiving only one course with no documented evidence of disease progression. Thus, 66 patients (93%) were evaluable for treatment response. The clinical characteristics of these evaluable patients are listed in Table 1 . The median age was 53 years (range 23 to 74 years), and 52% were men. All patients had aggressive lymphoma: 81% had diffuse large B-cell lymphoma, 8% had follicular center cell grade III lymphoma, 5% had anaplastic large-cell lymphoma, and 6% had transformed lymphoma. Sixty-five percent of the patients had received one prior treatment regimen, and 36% had received prior ara-C/platinum-based regimens. Forty-eight percent of the patients failed to achieve CR with their induction therapy and were thus considered to have primary refractory disease. Sixty-seven percent had elevated lactase dehydrogenase (LDH) levels before starting therapy. 0 Primary refractory is defined as failure to achieve a CR after induction therapy. Duration of response (months) Figure 1 . Duration of response for the 32 patients who achieved CR or PR as estimated by the Kaplan-Meier method. Twelve patients were censored at the time of receiving stem cell transplantation (n = 11) or grade 4 toxicity requiring change of therapy (n = 1). 
Response to therapy
A total of 199 courses were administered. The median number of courses per patient was three. Eighteen patients received only one course, 29 patients received two or three courses, seven patients received four or five courses, and 12 patients received six courses. Twelve responding patients received only two or three courses because they were offered treatment with high-dose chemotherapy followed by stem cell transplantation. Based on an intent-to-treat analysis, the overall response rate for the 71 eligible patients was 45% (95% CI: 33%-57%). Twenty-four patients achieved PR and eight patients achieved CR. When only the 66 evaluable patients were analyzed, the overall response rate was 48% (95% CI: 36%-61%) ( Table 2) , with a median duration of response of six months (Figure 1) . Patients who failed to achieve CR after induction therapy (primary refractory disease) had an overall response rate of 31%, compared with 65% for patients who did not have primary refractory disease (Table 2) . Similarly, patients who failed to respond to their last therapy (primary refractory or refractory relapse) had a response rate of 37%, compared with 64% response rate in patients who relapsed from their first or second CR (Table 2) . Prior exposure to ara-C/platinum-based regimens did not predict the outcome of paclitaxel plus topotecan therapy (Table 3) . However, patients who failed to respond to a prior ara-C/platinum-based regimen had a response rate of only 18% compared with 86% for patients who previously responded to ara-C/platinum programs. The overall response rates of patients who had received one or two prior treatment regimens were similar. However, when the data were analyzed according to disease sensitivity, patients who relapsed from their first or second CR had a higher response rate than those who were refractory to their first or second regimen (Table 4) .
Toxicity
Nonhematologic toxicity was predominantly grade 1 or 2, and all patients developed alopecia (Figure 2 ). There was no grade 4 nonhematologic toxicity. The hematologic toxicity is shown in Table 5 . Neutropenia of less than 100/ul was developed after 31 of 199 courses (16%), whereas platelet count of less than 10,000/ul was observed after five courses (3%). Grade 3-4 neutropenic fever was observed after 6% of the courses and grade Table 5 . Hematologic toxicity of 199 courses administered.
Toxicity n (%) Neutropeniâ 500/ul 64(32) 31 (16) 34 (17) 5 (3) 11 (6) 7 (4) Thrombocytopenia < 20,000/ul «l0.000/ul Neutropenic fever Grade 3-4 Infection Grade 3-4 Figure 4 . Box plot analysis of nadir platelet counts after each course of paclitaxel plus topotecan. The analysis shows that thrombocytopenia was not cumulative.
3-4 infection was observed after 4% of the courses. Neither neutropenia nor thrombocytopenia was cumulative ( Figures 3 and 4) . One patient was removed from the study because of a life-threatening sepsis requiring admission to an intensive care unit, but no treatmentrelated death occurred.
Discussion
We found that the combination of paclitaxel plus topotecan is effective cytoreductive program for the treatment of patients with refractory and relapsed aggressive NHL. Thirty-five percent of the patients were older than 60 years, 48% had primary refractory disease (defined as failure to achieve CR after induction therapy), 67% had an elevated serum LDH at the time of initiation of therapy, and 36% of the patients had received prior ara-C/platinum-based therapy. Despite these poor risk features paclitaxel plus topotecan achieved an encouraging overall response rate of 48%. To properly evaluate the effectiveness of a new therapy that is tested in a salvage setting, it is important to analyze responses according to disease sensitivity. In our experience, patients with primary refractory disease usually do not effectively respond to any type of salvage therapy. In contrast, patients who relapse from CR frequently respond to treatment. Therefore, if a clinical trial enrolls a large number of patients with primary refractory disease, a low overall response rate would be expected. Conversely, if a trial predominantly enrolls patients who relapsed from CR, then a high overall response rate of any salvage therapy would be expected. This observation mat account for the differences in response rates reported with single agent paclitaxel by different groups [7, [13] [14] [15] . For this reason, we analyzed the results of this trial according to disease sensitivity (Table 2 ). In this study, patients who had primary refractory disease had a response rate of 31% compared with 65% for patients who did not. These results compare favorably with the experience using each drug alone (Table 6 ). In patients with primary refractory disease, paclitaxel achieved a 15% response rate whereas topotecan achieved a 12% response rate [7, 8] . At our institution, patients with relapsed disease had a 50% response rate using paclitaxel alone and a 43% response rate using topotecan alone. Therefore the combination of paclitaxel and topotecan seems to have improved the response rate in both disease categories.
In this study, the median duration of response was six months, which is similar to the response duration for other salvage programs [4, 16] . Although these salvage programs are not expected to be curative, they can reduce the tumor burden and may prepare patients for stem cell transplantation. These salvage programs can also provide good palliation in patients who are not eligible for bone marrow transplantation. In this study, two patients who responded to paclitaxel plus topotecan but were not eligible for stem cell transplantation achieved CR that lasted for 22 and 26+ months. Because this paclitaxel plus topotecan program do not contain anthracycline it can be given to patients who have a boarder line left ventricular ejection fraction. Unlike the cis-platinum-based programs, paclitaxel plus topotecan does not require aggressive hydration and has no renal toxicity.
The encouraging response rate achieved by paclitaxel plus topotecan could provide an impetus for new programs that could be tested in untreated patients with aggressive NHL who have poor risk features. These patients have a low probability of cure when treated with CHOP or CHOP-like therapy and new effective programs are needed for this patient population.
